Log In
BCIQ
Print this Print this
 

pidilizumab (CT-011, MDV9300)

  Manage Alerts
Collapse Summary General Information
Company CureTech Ltd.
DescriptionHumanized mAb against an undisclosed target
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$23,266.0M

$22,936.0M

$330.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today